LumiraDx Limited (LMDX)
| Market Cap | 22.76M |
| Revenue (ttm) | 126.52M |
| Net Income (ttm) | -338.04M |
| Shares Out | 361.79M |
| EPS (ttm) | -1.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,127,079 |
| Open | 0.064 |
| Previous Close | 0.064 |
| Day's Range | 0.058 - 0.065 |
| 52-Week Range | 0.058 - 1.330 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 1.42 (+1,189.74%) |
| Earnings Date | Jan 9, 2024 |
About LMDX
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnos... [Read more]
Financial Performance
In 2022, LumiraDx's revenue was $254.48 million, a decrease of -39.62% compared to the previous year's $421.43 million. Losses were -$447.79 million, 343.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for LMDX stock is "Buy." The 12-month stock price forecast is $1.42, which is an increase of 1,189.74% from the latest price.
News
Roche to buy part of LumiraDx diagnostics platform for $295 million
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators ...
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of T...
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
LumiraDx Reports Second Quarter 2023 Results
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended Jun...
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on...
LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional N...
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraD...
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has received validation for use by the MHRA under the CTDA process for the LumiraDx SARS-CoV-2 Ag Ultr...
LumiraDx Reports First Quarter 2023 Results
LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March...
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on T...
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
LONDON, April 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that i...
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
LONDON, April 06, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost Res...
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full...
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 f...
LumiraDx to Present at Raymond James Institutional Investors Conference
LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institu...
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has rega...
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of car...
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it...
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test's ongoing development and future launch into developing countries Company receives $14.2M in grants fr...
Latest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” LumiraDx shares these and other findings from its second annual U.S. survey ...
Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings
LumiraDx shares these and other findings from its first annual U.K. survey “Point of Care Diagnostics: A Clinicians View” LumiraDx shares these and other findings from its first annual U.K. survey “Po...
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of...
LumiraDx Reports Third Quarter 2022 Results
Progress on Near-Term Growth Opportunities and Cost Savings Progress on Near-Term Growth Opportunities and Cost Savings
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on ...